Report cover image

Global Human Cytomegalovirus Envelope Glycoprotein B Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 16, 2025
Length 197 Pages
SKU # APRC20280331

Description

Summary

According to APO Research, the global Human Cytomegalovirus Envelope Glycoprotein B market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Human Cytomegalovirus Envelope Glycoprotein B is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Human Cytomegalovirus Envelope Glycoprotein B is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Human Cytomegalovirus Envelope Glycoprotein B market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Human Cytomegalovirus Envelope Glycoprotein B is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Human Cytomegalovirus Envelope Glycoprotein B market include Vical Incorporated, VBI Vaccine Inc, Vakzine Projekt Management GmbH, Trellis Bioscience, Inc. and Astellas Pharma Inc., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Human Cytomegalovirus Envelope Glycoprotein B, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Human Cytomegalovirus Envelope Glycoprotein B, also provides the sales of main regions and countries. Of the upcoming market potential for Human Cytomegalovirus Envelope Glycoprotein B, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Human Cytomegalovirus Envelope Glycoprotein B sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Human Cytomegalovirus Envelope Glycoprotein B market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Human Cytomegalovirus Envelope Glycoprotein B sales, projected growth trends, production technology, application and end-user industry.

Human Cytomegalovirus Envelope Glycoprotein B Segment by Company

Vical Incorporated
VBI Vaccine Inc
Vakzine Projekt Management GmbH
Trellis Bioscience, Inc.
Astellas Pharma Inc.
Human Cytomegalovirus Envelope Glycoprotein B Segment by Type

CSJ-148
CyMVectin
PPCM
TRL-345
Cytomegalovirus Vaccine
Others
Human Cytomegalovirus Envelope Glycoprotein B Segment by Application

Infectious Disease
Women's Health
Oncology
Others
Human Cytomegalovirus Envelope Glycoprotein B Segment by Region

North America

United States
Canada
Europe

Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific

China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America

Mexico
Brazil
Argentina
Colombia
Middle East & Africa

Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Human Cytomegalovirus Envelope Glycoprotein B status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Human Cytomegalovirus Envelope Glycoprotein B market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Human Cytomegalovirus Envelope Glycoprotein B significant trends, drivers, influence factors in global and regions.
6. To analyze Human Cytomegalovirus Envelope Glycoprotein B competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Cytomegalovirus Envelope Glycoprotein B market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Cytomegalovirus Envelope Glycoprotein B and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Cytomegalovirus Envelope Glycoprotein B.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Cytomegalovirus Envelope Glycoprotein B market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Cytomegalovirus Envelope Glycoprotein B industry.
Chapter 3: Detailed analysis of Human Cytomegalovirus Envelope Glycoprotein B manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Human Cytomegalovirus Envelope Glycoprotein B in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Human Cytomegalovirus Envelope Glycoprotein B in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value (2020-2031)
1.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume (2020-2031)
1.2.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Human Cytomegalovirus Envelope Glycoprotein B Market Dynamics
2.1 Human Cytomegalovirus Envelope Glycoprotein B Industry Trends
2.2 Human Cytomegalovirus Envelope Glycoprotein B Industry Drivers
2.3 Human Cytomegalovirus Envelope Glycoprotein B Industry Opportunities and Challenges
2.4 Human Cytomegalovirus Envelope Glycoprotein B Industry Restraints
3 Human Cytomegalovirus Envelope Glycoprotein B Market by Company
3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Company Revenue Ranking in 2024
3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Company (2020-2025)
3.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Company (2020-2025)
3.4 Global Human Cytomegalovirus Envelope Glycoprotein B Average Price by Company (2020-2025)
3.5 Global Human Cytomegalovirus Envelope Glycoprotein B Company Ranking (2023-2025)
3.6 Global Human Cytomegalovirus Envelope Glycoprotein B Company Manufacturing Base and Headquarters
3.7 Global Human Cytomegalovirus Envelope Glycoprotein B Company Product Type and Application
3.8 Global Human Cytomegalovirus Envelope Glycoprotein B Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Human Cytomegalovirus Envelope Glycoprotein B Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Human Cytomegalovirus Envelope Glycoprotein B Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Human Cytomegalovirus Envelope Glycoprotein B Market by Type
4.1 Human Cytomegalovirus Envelope Glycoprotein B Type Introduction
4.1.1 CSJ-148
4.1.2 CyMVectin
4.1.3 PPCM
4.1.4 TRL-345
4.1.5 Cytomegalovirus Vaccine
4.1.6 Others
4.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Type
4.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Type (2020-2031)
4.2.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume Share by Type (2020-2031)
4.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Type
4.3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Type (2020-2031)
4.3.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type (2020-2031)
5 Human Cytomegalovirus Envelope Glycoprotein B Market by Application
5.1 Human Cytomegalovirus Envelope Glycoprotein B Application Introduction
5.1.1 Infectious Disease
5.1.2 Women's Health
5.1.3 Oncology
5.1.4 Others
5.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Application
5.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume by Application (2020-2031)
5.2.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Volume Share by Application (2020-2031)
5.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Application
5.3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Application (2020-2031)
5.3.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application (2020-2031)
6 Human Cytomegalovirus Envelope Glycoprotein B Regional Sales and Value Analysis
6.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region (2020-2031)
6.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region: 2020-2025
6.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region (2026-2031)
6.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Region (2020-2031)
6.4.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Region: 2020-2025
6.4.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Region (2026-2031)
6.5 Global Human Cytomegalovirus Envelope Glycoprotein B Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Human Cytomegalovirus Envelope Glycoprotein B Sales Value (2020-2031)
6.6.2 North America Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales Value (2020-2031)
6.7.2 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales Value (2020-2031)
6.8.2 Asia-Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Human Cytomegalovirus Envelope Glycoprotein B Sales Value (2020-2031)
6.9.2 South America Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Human Cytomegalovirus Envelope Glycoprotein B Sales Value (2020-2031)
6.10.2 Middle East & Africa Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Country, 2024 VS 2031
7 Human Cytomegalovirus Envelope Glycoprotein B Country-level Sales and Value Analysis
7.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2020-2031)
7.3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2020-2025)
7.3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2026-2031)
7.4 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Country (2020-2031)
7.4.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Country (2020-2025)
7.4.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.5.2 USA Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.6.2 Canada Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.8.2 Germany Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.9.2 France Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.9.3 France Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.11.2 Italy Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.12.2 Spain Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.13.2 Russia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.16.2 China Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.16.3 China Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.17.2 Japan Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.19.2 India Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.19.3 India Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.20.2 Australia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.24.2 Chile Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.26.2 Peru Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.28.2 Israel Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.29.2 UAE Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.31.2 Iran Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Human Cytomegalovirus Envelope Glycoprotein B Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Human Cytomegalovirus Envelope Glycoprotein B Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Vical Incorporated
8.1.1 Vical Incorporated Comapny Information
8.1.2 Vical Incorporated Business Overview
8.1.3 Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Sales, Value and Gross Margin (2020-2025)
8.1.4 Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
8.1.5 Vical Incorporated Recent Developments
8.2 VBI Vaccine Inc
8.2.1 VBI Vaccine Inc Comapny Information
8.2.2 VBI Vaccine Inc Business Overview
8.2.3 VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Sales, Value and Gross Margin (2020-2025)
8.2.4 VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
8.2.5 VBI Vaccine Inc Recent Developments
8.3 Vakzine Projekt Management GmbH
8.3.1 Vakzine Projekt Management GmbH Comapny Information
8.3.2 Vakzine Projekt Management GmbH Business Overview
8.3.3 Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Sales, Value and Gross Margin (2020-2025)
8.3.4 Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
8.3.5 Vakzine Projekt Management GmbH Recent Developments
8.4 Trellis Bioscience, Inc.
8.4.1 Trellis Bioscience, Inc. Comapny Information
8.4.2 Trellis Bioscience, Inc. Business Overview
8.4.3 Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales, Value and Gross Margin (2020-2025)
8.4.4 Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
8.4.5 Trellis Bioscience, Inc. Recent Developments
8.5 Astellas Pharma Inc.
8.5.1 Astellas Pharma Inc. Comapny Information
8.5.2 Astellas Pharma Inc. Business Overview
8.5.3 Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales, Value and Gross Margin (2020-2025)
8.5.4 Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
8.5.5 Astellas Pharma Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Human Cytomegalovirus Envelope Glycoprotein B Value Chain Analysis
9.1.1 Human Cytomegalovirus Envelope Glycoprotein B Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Human Cytomegalovirus Envelope Glycoprotein B Sales Mode & Process
9.2 Human Cytomegalovirus Envelope Glycoprotein B Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Human Cytomegalovirus Envelope Glycoprotein B Distributors
9.2.3 Human Cytomegalovirus Envelope Glycoprotein B Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.